Analysis of Clinical Efficacy and Prognosis in 83 Cases Receiving Haploidentical Hematopoietic Stem Cell Transplantation for Hematological Malignancies.
- Author:
Meng WANG
1
;
Yu-Jun DONG
2
;
Zhi-Xiang QIU
2
;
Wei LIU
2
;
Han-Yun REN
3
Author Information
- Publication Type:Journal Article
- MeSH: Disease-Free Survival; Graft vs Host Disease; epidemiology; Hematologic Neoplasms; diagnosis; therapy; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Prognosis; Recurrence; Risk Factors; Siblings; Survival Analysis; Treatment Outcome
- From: Journal of Experimental Hematology 2016;24(3):833-839
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo summarize the clinical experience and evaluate the efficacy of haploidentical HSCT.
METHODSThe survival rates of 156 patients receiving either haploidentical (83 cases) or HLA-identical (73 cases) transplantation for hematologic diseases were compared and risk factors related to overall survival (OS) were analyzed.
RESULTSHLA-identical and haploidentical cohorts were not statistically different in the hematopoietic reconstitution, incidence of acute and chronic graft-versus-host disease (GVHD), OS, disease-free survival (DFS), relapse and treatment-related mortality (TRM) after transplantation. Multivariate analysis showed that advanced disease status, relapse and grade III-IV acute GVHD were independent prognostic indictors for OS with relative risk (RR) of 4.8 (95% CI 2.2-10.1), 4.3 (95% CI 2.6-8.0) and 3.3 (95% CI 1.6-7.0), respectively (P<0.05).
CONCLUSIONHaploidentical transplantation with the present conditioning can achieve the therapeutic effects comparable to HLA-identical sibling transplantation. Disease status before transplantation and the presence or not of severe GVHD after transplantation have important significance for the long-term survival after transplantation.
